Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-AML-101 in newly diagnosed acute myeloid leukemia
ISRCTN71474257Phase 2Terminated
- Sponsor
- DIDACT Foundation
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of magrolimab, venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by DIDACT Foundation. Primary endpoint: Event-free survival. Started Jan 2024; status: terminated.
02
Drugs
magrolimabvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN71474257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71474257.